

RESPONSE EVALUATION IN NEUROFIBROMATOSIS AND SCHWANNOMATOSIS (REiNS): SUPPLEMENT II

INTRODUCTION

- S1 Consensus for NF clinical trials: Recommendations of the REiNS collaboration (Supplement II)
B.C. Widemann and S.R. Plotkin

ARTICLES

- S4 Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials
P.L. Wolters, S. Martin, V.L. Merker, J.H. Tongsard, S.E. Solomon, A. Baldwin, A.L. Bergner, K. Walsh, H.L. Thompson, K.L. Gardner, C.M. Hingtgen, E. Schorry, W.N. Dudley, and B. Franklin, for the REiNS International Collaboration
- S10 Comment: Clinical outcome assessments in transition
R.H. Dworkin
- S13 Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1
S.R. Plotkin, S.D. Davis, K.A. Robertson, S. Akshintala, J. Allen, M.J. Fisher, J.O. Blakeley, B.C. Widemann, R.E. Ferner, and C.L. Marcus, for the REiNS International Collaboration

- S21 Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention
K.S. Walsh, J. Janusz, P.L. Wolters, S. Martin, B.P. Klein-Tasman, M.A. Toledo-Tamula, H.L. Thompson, J.M. Payne, K.K. Hardy, P. de Blank, C. Semerjian, L.S. Gray, S.E. Solomon, and N. Ullrich, for the REiNS International Collaboration

- S31 Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis
S. Ahlawat, L.M. Fayad, M.S. Khan, M.A. Bredella, G.J. Harris, D.G. Evans, S. Farschtschi, M.A. Jacobs, A. Chhabra, J.M. Salamon, R. Wenzel, V.F. Mautner, E. Dombi, W. Cai, S.R. Plotkin, and J.O. Blakeley, on behalf of the Whole Body MRI Committee for the REiNS International Collaboration

- S40 Current status and recommendations for biomarkers and biobanking in neurofibromatosis
C.O. Hanemann, J.O. Blakeley, F.P. Nunes, K. Robertson, A. Stemmer-Rachamimov, V. Mautner, A. Kurtz, M. Ferguson, B.C. Widemann, D.G. Evans, R. Ferner, S.L. Carroll, B. Korf, P. Wolkenstein, P. Knight, and S.R. Plotkin, for the REiNS International Collaboration

Publication of this supplement was supported by the Children's Tumor Foundation.

The authors gratefully acknowledge the participation of the entire REiNS community, the Food and Drug Administration (Martha Donoghue, Denise Casey), and the Cancer Therapy Evaluation Program (Helen Chen, William Timmer) at the National Cancer Institute.

Neurology®

87 (7 Supplement 1)
Neurology 2016;87:S10-S12

This information is current as of January 1, 2016

**Updated Information &
Services**

including high resolution figures, can be found at:
http://n.neurology.org/content/87/7_Supplement_1.citation.full

Permissions & Licensing

Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878.
Online ISSN: 1526-632X.

